Immunocore Limited has entered into a partnership with GlaxoSmithKline for multiple novel targets not addressable using antibody-based technologies.
Biopharma News
Advertisement
The $1-billion deal includes select parts of Merck?s manufacturing site in Oss, The Netherlands and Sioux City, Iowa as well as 11 finished products.
The companies agree to jointly develop and promote MOR202, an oncology mAb in a deal potentially valued at more than $800 million.
FDA Discovers Microbial Contamination in Compound Pharmacy Products
The company is cited for using unapproved visual-inspection methods for finished parenteral drugs and conducting inadequate visual inspections.
Modular containment room at Belfast facility allows studies of biologics and vaccines.
Program aims to develop a novel oral treatment.
Advertisement
Advertisement